Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University462 Ruijin Hospital282 Shanghai Zhongshan Hospital169 RenJi Hospital133 Children's Hospital of Fudan University84
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Shanghai

3879 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
NCT06085690CRBSI - Catheter Related Bloodstream Infection, Evidence-based Nursing Practice, Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Associated Bloodstream Infection
Fudan University
Not applicable
8,050
Shanghai
2023-09-04
Recruiting
HuidaGene Therapeutics Co., Ltd.
Early Phase 1
12
Shanghai, Tianjin
2023-09-04
Active, closed
Shanghai BDgene Co., Ltd.
Phase 1
16
Shanghai, Hangzhou, Wenzhou
2023-09-04
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
56
Shanghai
2023-09-03
Recruiting
Shanghai Mental Health Center
Not applicable
60
Shanghai
2023-09-01
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 1
172
Bengbu, Changsha, Shanghai
2023-09-01
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
668
Nanjing, Shanghai
2023-09-01
Not yet open
Fudan University
Observational
302
Shanghai
2023-09-01
Recruiting
RenJi Hospital
Observational
240
Shanghai
2023-09-01
Recruiting
Obesity Queue Database
NCT06391320Obesity
RenJi Hospital
Observational
5,000
Shanghai
2023-09-01
Recruiting
RenJi Hospital
Observational
500
Shanghai
2023-09-01
Recruiting
Xiaohua Wu
Phase 2
30
Shanghai
2023-09-01
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Huashan Hospital
Observational
180
Shanghai
2023-08-31
Recruiting
Ruijin Hospital
Observational
50
Shanghai
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
200
Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
2023-08-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
Ruijin Hospital
Observational
3,000
Shanghai
2023-08-25
Recruiting
Shanghai Jiatan Pharmatech Co., Ltd
Phase 2
20
Shanghai
2023-08-25
Recruiting
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
RenJi Hospital
Phase 2
28
Shanghai
2023-08-23
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu
2023-08-22
Recruiting
Fudan University
Phase 2
82
Shanghai
2023-08-22
Recruiting
Fudan University
Phase 3
424
Shanghai
2023-08-20
Recruiting
Changhai Hospital
Early Phase 1
36
Shanghai
2023-08-20
Recruiting
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
NCT06972511Oligometastatic Prostate Cancer
RenJi Hospital
Phase 2/3
120
Shanghai
2023-08-20
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
NCT05840016Advanced Squamous Non Small Cell Lung Cancer
Akeso
Phase 3
532
Shanghai
2023-08-17
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
2,000
Shanghai
2023-08-15
Recruiting
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1
9
Shanghai
2023-08-15
Active, closed
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Early Phase 1
7
Shanghai
2023-08-14
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Active, closed
Fudan University
Phase 2
202
Shanghai
2023-08-10
Active, closed
BAIYONG SHEN
Observational
150
Shanghai
2023-08-09
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Active, closed
nthalmic Pty Ltd
Not applicable
441
Wenzhou, Tianjin, Shanghai
2023-08-04
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
100
Shanghai
2023-08-03
Recruiting
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
DrugBL-M11D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Recruiting
Fudan University
Observational
100
Shanghai
2023-08-01
Recruiting
International Peace Maternity and Child Health Hospital
Not applicable
858
Shanghai
2023-08-01
By invitation
Ma Yanlei
Observational
500
Shanghai
2023-08-01
Recruiting
Changhai Hospital
Not applicable
206
Shanghai
2023-08-01
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
NCT05954078High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Phase 3
340
Shanghai
2023-08-01
Active, closed
Shanghai Zhongshan Hospital
Phase 1/2
78
Shanghai
2023-08-01
Active, closed
HOYA Lens Thailand LTD.
Not applicable
249
Beijing, Guangzhou, Shanghai, Shengyang, Tianjin
2023-07-31
Not yet open
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Recruiting
Ruijin Hospital
Not applicable
1,355
Shanghai
2023-07-28
Recruiting
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Recruiting
LaNova Medicines Zhejiang Co., Ltd.
Phase 2
632
Shanghai
2023-07-27
Recruiting
Fudan University
Phase 2
265
Shanghai
2023-07-26
Active, closed
Fudan University
Phase 2
88
Shanghai
2023-07-26
Recruiting
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
27
Hangzhou, Shanghai
2023-07-24
Recruiting
Fudan University
Phase 2
50
Shanghai
2023-07-20
Recruiting
Fudan University
Phase 2
20
Shanghai
2023-07-20
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
198
Shanghai
2023-07-19
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
365
Shanghai
2023-07-18
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
110
Shanghai
2023-07-13
Active, closed
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Active, closed
Fudan University
Phase 2
50
Shanghai
2023-07-10
Active, closed
Shanghai Henlius Biotech
Phase 2
132
Xuzhou, Shanghai
2023-07-10
Recruiting
Yin Ping
Not applicable
204
Shanghai
2023-07-07
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
220
Shanghai, Tianjin
2023-07-06
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Active, closed
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
Shanghai NewMed Medical Co., Ltd.
Not applicable
73
Shanghai
2023-07-05
Recruiting
Hrain Biotechnology Co., Ltd.
Early Phase 1
18
Shanghai
2023-07-04
Recruiting
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2
25
Shanghai
2023-07-03
Not yet open
Fudan University
Not applicable
176
Shanghai
2023-07-01
Recruiting
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
NCT06120426Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
Shanghai Changzheng Hospital
Observational
182
Shanghai
2023-07-01
Recruiting
Shanghai Minimally Invasive Surgery Center
Not applicable
356
Shanghai
2023-07-01
Recruiting
Shanghai 6th People's Hospital
Phase 1/2
24
Shanghai
2023-07-01
Recruiting
A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma
NCT05940441to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma
DrugCapecitabine
Eye & ENT Hospital of Fudan University
Observational
74
Shanghai
2023-07-01
Recruiting
Children's Hospital of Fudan University
Not applicable
356
Shanghai
2023-07-01
Recruiting
Non-invasive BCI and Application Verification for Depressed People
NCT06417437Depression, Major Depressive Disorder, Bipolar Depression
DrugSSRI
Shanghai Mental Health Center
Phase 4
400
Shanghai
2023-07-01
Not yet open
RenJi Hospital
Not applicable
100
Shanghai
2023-07-01
Recruiting
Standardized Nutritional Management of Pediatric Patients With Solid Tumors
NCT06730204Tumor, Solid, Children, Nutritional Intervention
Children's Hospital of Fudan University
Not applicable
400
Shanghai
2023-07-01
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
NCT05965115Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Shanghai Zhongshan Hospital
Observational
10,000
Shanghai
2023-07
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Active, closed
Shanghai Chest Hospital
Phase 2
54
Shanghai
2023-06-27
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
38
Shanghai
2023-06-25
Active, closed
Kun Sun
Not applicable
12
Chengdu, Shanghai
2023-06-25
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
Shanghai East Hospital
Early Phase 1
30
Shanghai
2023-06-21
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 4
368
Shanghai
2023-06-20
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
480
Shanghai
2023-06-19
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
NCT05901558Autism Spectrum Disorder, Therapy
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2023-06-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
NCT05912816Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
DrugsDisitamab Vedotin·Tislelizumab
RenJi Hospital
Phase 2
20
Shanghai
2023-06-10
Recruiting
Shanghai Zhongshan Hospital
Not applicable
102
Shanghai
2023-06-10
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
Children's Hospital of Fudan University
Not applicable
240
Shanghai
2023-06-07
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-06-05
Active, closed
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
236
Shanghai
2023-06-03
Recruiting
Hoffmann-La Roche
Phase 3
200
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Recruiting
Fudan University
Phase 3
606
Shanghai
2023-06-01
Recruiting
Ruijin Hospital
Phase 2
86
Shanghai
2023-06-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-06-01
Recruiting
Wenjin Yin
Not applicable
86
Shanghai
2023-06-01
Recruiting
Fudan University
Phase 2
1,008
Shanghai
2023-06-01
Active, closed
MRD in High-risk EBC
NCT06566729Breast Cancer
Shanghai Jiao Tong University School of Medicine
Observational
125
Shanghai
2023-06-01
Recruiting
RenJi Hospital
Observational
45
Shanghai
2023-06-01
Recruiting
Ruijin Hospital
Phase 2
43
Shanghai
2023-06-01
Recruiting
Ruijin Hospital
Observational
332
Shanghai
2023-06-01
Recruiting
Shanghai Cell Therapy Group Co.,Ltd
Early Phase 1
12
Shanghai
2023-06-01
Recruiting
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
NCT05901428Hormone Receptor Positive HER-2 Negative Breast Cancer
DrugsEpirubicin·Docetaxel·Cyclophosphamide·Carboplatin
Fudan University
Phase 3
1,736
Shanghai
2023-06-01
Recruiting
RenJi Hospital
Phase 3
488
Shanghai
2023-06-01
Recruiting
RenJi Hospital
Not applicable
120
Shanghai
2023-05-31
Recruiting
Shanghai Zhongshan Hospital
Not applicable
200
Shanghai
2023-05-31
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
DrugMHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
16
Shanghai
2023-05-23
By invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
DrugBRL-301
Bioray Laboratories
Not applicable
15
Shanghai
2023-05-17
Recruiting
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
30
Huai'an, Nanchang, Shanghai, Guangzhou
2023-05-15
Recruiting
Pilot Study of AuTNA I
NCT05853107Retinitis Pigmentosa
Eye & ENT Hospital of Fudan University
Not applicable
7
Shanghai
2023-05-12
Recruiting
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3
242
Shanghai
2023-05-11
Recruiting
RenJi Hospital
Early Phase 1
18
Shanghai
2023-05-11
Recruiting
Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study
NCT05864638Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy, Thrombosis
Changhai Hospital
Observational
10,000
Shanghai
2023-05-10
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Recruiting
Shanghai Institute of Hypertension
Not applicable
10,000
Shanghai
2023-05-06
Recruiting
Gongji Pregnancy Endorine Cohort Study
NCT07125885Gestatiaonl Diabetes Mellitus, Thyroid Disease Pregnancy, Hyperglycemia in Pregnant Diabetic Patients
Shanghai General Hospital, China
Observational
3,000
Shanghai
2023-05-05
Recruiting
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
NCT05688488Glottic Web of Larynx, Laryngeal Stenosis, Glottic Carcinoma, Laryngeal Leucoplakia
DrugMitomycin C
Eye & ENT Hospital of Fudan University
Phase 1/2
100
Shanghai
2023-05-05
Recruiting
RC48-ADC in HER2-low Advanced Breast Cancer
NCT05831878Advanced Breast Cancer
DrugDisitamab Vedotin
RenJi Hospital
Not applicable
36
Shanghai
2023-05-04
Recruiting
Ruijin Hospital
Phase 4
8
Shanghai
2023-05-01
Not yet open
Xin Cai
Phase 2
31
Shanghai
2023-05-01
Active, closed
Drug Induced Liver Disease Study Group
Observational
2,000
Shanghai
2023-05-01
Active, closed
RenJi Hospital
Phase 2
40
Shanghai
2023-05-01
Recruiting
The University of Hong Kong
Not applicable
100
Shanghai
2023-05-01
Recruiting
Shanghai University of Traditional Chinese Medicine
Not applicable
367
Shanghai
2023-05-01
Not yet open
Fudan University
Phase 2
47
Shanghai
2023-05-01
Active, closed
Shanghai Changzheng Hospital
Phase 2
30
Shanghai
2023-05-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
94
Shanghai
2023-05-01
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
DrugLinperlisib
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Not yet open
Shanghai Zhongshan Hospital
Not applicable
4,648
Shanghai
2023-05
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Recruiting
RenJi Hospital
Observational
172
Shanghai
2023-04-30
Active, closed
Study of CT071 Injection in RRMM or PPCL
NCT05838131Multiple Myeloma, Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
Early Phase 1
20
Shanghai
2023-04-28
Recruiting
Fudan University
Phase 3
134
Shanghai
2023-04-25
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Chinese Academy of Medical Sciences, Fuwai Hospital
Early Phase 1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2023-04-20
Recruiting
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
424
Shanghai
2023-04-20
Recruiting
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
DrugsMevrometostat·Xtandi·Enzalutamide
Evopoint Biosciences Inc.
Phase 1/2
307
Jinan, Shanghai
2023-04-19
Recruiting
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Active, closed
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
100
Shanghai
2023-04-15
Active, closed
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Recruiting
Lepu Biopharma Co., Ltd.
Phase 3
180
Shanghai
2023-04-04
Active, closed
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Recruiting
Children's Hospital of Fudan University
Not applicable
60
Shanghai
2023-04-01
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Recruiting
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
30
Shanghai
2023-04-01
Recruiting
Fudan University
Phase 3
390
Shanghai
2023-03-31
Recruiting
Shanghai Tong Ren Hospital
Phase 2
58
Shanghai
2023-03-31
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT05759793Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
DrugCar-T
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
12
Shanghai
2023-03-30
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
DrugCamrelizumab
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05768529Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
100
Changsha, Suzhou, Shanghai
2023-03-28
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Active, closed
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Shanghai
2023-03-27
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Recruiting
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
258
Shanghai
2023-03-14
Recruiting
China Children Eye Study
NCT05770661Axial Length, Myopia, Child Development
Shanghai Eye Disease Prevention and Treatment Center
Observational
30,000
Shanghai
2023-03-10
Active, closed
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
Longitudinal Data Registry of Plasma Cell Dyscrasia
NCT06760052Multiple Myeloma and Other Plasma Cell Neoplasms
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-03-01
Recruiting
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
NCT05870969Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
Ruijin Hospital
Observational
20,000
Shanghai
2023-03-01
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
6
Shanghai
2023-03-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2023-03-01
Active, closed
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Zhaoshen Li
Observational
100
Shanghai
2023-03-01
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Not yet open
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
NCT05847855Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
Fudan University
Observational
1,000
Shanghai, Chengdu
2023-02-27
Active, closed
AR Training in Adults With Unilateral Amblyopia
NCT06704737Amblyopia Unilateral, Amblyopia Functional
Eye & ENT Hospital of Fudan University
Not applicable
48
Shanghai
2023-02-25
Recruiting
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
NCT06369714Attention Deficit Disorder With Hyperactivity, Executive Function Disorder
DrugConcerta
Lei Lei, MD
Not applicable
210
Shanghai
2023-02-24
Active, closed
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT05717348Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugES014
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 1
120
Shanghai
2023-02-24
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Active, closed
Ruijin Hospital
Observational
112
Shanghai
2023-02-17
Recruiting
Dizal Pharmaceuticals
Phase 2
60
Shanghai
2023-02-15
Recruiting
Fudan University
Phase 3
307
Shanghai
2023-02-15
Recruiting
Ruijin Hospital
Phase 1/2
264
Shanghai
2023-02-13
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
70
Shanghai
2023-02-10
Recruiting
Children's Cancer Group, China
Phase 3
200
Shanghai, Chengdu
2023-02-06
Recruiting
Ruijin Hospital
Phase 2
55
Shanghai
2023-02-06
Active, closed
Applied Pharmaceutical Science, Inc.
Phase 1
108
Shanghai
2023-02-06
Active, closed
Assessment of DOT Spectacles in Chinese Children
NCT05562622Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
195
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2023-02-05
Recruiting
Autoimmune Hepatitis Cohort in China
NCT05785793Autoimmune Hepatitis
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-02-01
Recruiting
Shanghai Zhongshan Hospital
Not applicable
200
Shanghai
2023-02-01
Recruiting
Shanghai Zhongshan Hospital
Not applicable
300
Shanghai
2023-02-01
Recruiting
Frontera Therapeutics
Early Phase 1
18
Beijing, Shanghai
2023-02-01
Active, closed
Xuebo Liu
Observational
301
Shanghai
2023-02-01
Recruiting
Fudan University
Phase 2
200
Shanghai
2023-02-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
100
Shanghai
2023-02-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Early Phase 1
6
Shanghai
2023-01-30
Recruiting
Aibin Liang，MD，Ph.D.
Phase 1/2
48
Shanghai
2023-01-18
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Recruiting
Huashan Hospital
Phase 2/3
2,442
Guiyang, Kaili, Liupanshui, Zunyi, Shanghai, Zhuji
2023-01-13
Recruiting
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an
2023-01-12
Recruiting
LaNova Medicines Limited
Phase 1/2
139
Guangzhou, Wuhan, Linyi, Beijing, Shanghai
2023-01-11
Recruiting
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
NCT06173986Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
DrugsPD-1inhibitor·Nab-paclitaxel·Cisplatin
Shanghai Chest Hospital
Phase 1/2
50
Shanghai
2023-01-10
Active, closed
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
9
Shanghai
2023-01-10
Recruiting
Shanghai Proton and Heavy Ion Center
Phase 2
67
Shanghai
2023-01-10
Active, closed
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Recruiting
Akeso
Phase 3
570
Shanghai
2023-01-05
Recruiting
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
DrugT-Bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
26
Shanghai
2023-01-05
Recruiting
Yin Ping
Not applicable
360
Shanghai
2023-01-04
Active, closed
TCM Daoyin Therapy in Individuals At-risk for COPD
NCT05940480Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive
Shanghai University of Traditional Chinese Medicine
Not applicable
60
Shanghai
2023-01-03
Recruiting
Shanghai Chest Hospital of Shanghai Jiao Tong University
Observational
38
Shanghai
2023-01-03
Recruiting
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
300
Shanghai
2023-01-01
By invitation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
240
Shanghai
2023-01-01
Recruiting
Shanghai Cell Therapy Group Co.,Ltd
Early Phase 1
16
Shanghai
2023-01-01
Recruiting
RenJi Hospital
Observational
480
Shanghai
2023-01-01
Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
100
Shanghai
2023-01-01
Recruiting
RenJi Hospital
Not applicable
12
Shanghai
2023-01-01
By invitation
Optimized PGT-M Strategy for Patients With No Proband
NCT06722313De Novo Mutation, Preimplantation Genetic Testing, Without Proband
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
5
Shanghai
2023-01-01
Recruiting
Shanghai Cancer Hospital, China
Phase 3
300
Shanghai
2023-01-01
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
DrugsHerceptin·Trastuzumab
Fudan University
Phase 2
55
Shanghai
2023-01-01
Active, closed
Changhai Hospital
Not applicable
410
Shanghai
2023-01-01
Recruiting
Fudan University
Phase 2
114
Shanghai
2023-01-01
Recruiting
Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
NCT06993636Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban, Anticoagulant Drugs
Children's Hospital of Fudan University
Observational
60
Shanghai
2023-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
323
Jiangxi, Shanghai, Hangzhou
2023-01-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
633
Shanghai
2023-01-01
Recruiting
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
NCT06653517Ameloblastoma, BRAF V600E Mutation Positive
DrugsDabrafenib·Trametinib
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
12
Shanghai
2023-01-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
148
Beijing, Jinan, Shanghai
2023-01
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
DrugsCarrelizumab·SHR-A1921·SHR-A2009·Famitinib
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
Fudan University
Early Phase 1
24
Shanghai
2022-12-28
Recruiting
Ruijin Hospital
Observational
7,062
Shanghai
2022-12-28
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in SheMountain
NCT05667935Alzheimer Disease, Dementia, Neurodegenerative Diseases, Cognitive Impairment
Ruijin Hospital
Observational
2,000
Shanghai
2022-12-26
Recruiting
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT05757336Gallbladder Cancer, Initially Unresectable, the First Line Treatment
Lu Wang, MD, PhD
Phase 2
50
Shanghai
2022-12-22
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Recruiting
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Recruiting
Fudan University
Phase 2
34
Shanghai
2022-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
70
Shanghai
2022-12-08
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
632
Shanghai
2022-12-08
Active, closed
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Not yet open
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
NCT05359393Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
Fudan University
Phase 2
52
Shanghai
2022-12-01
Active, closed
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
Regeneron Pharmaceuticals
Phase 3
63
Shanghai
2022-11-21
Active, closed
Digital Therapy for Fatty Liver Disease
NCT07007741Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
141
Shanghai
2022-11-19
Active, closed
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
NCT05550740High Myopia, Refractive Errors, Eye Diseases
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
30
Shanghai
2022-11-19
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
AK112 in Advanced Non-Small Cell Lung Cancer
NCT05499390Advanced Non-small-cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Akeso
Phase 3
398
Shanghai
2022-11-09
Active, closed
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
74
Shanghai, Chengdu
2022-11-08
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
DrugVenetocalx
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
By invitation
Peking University International Hospital
Phase 4
102
Beijing, Qingdao, Shanghai, Xi’an
2022-11-01
Recruiting
Shanghai University of Traditional Chinese Medicine
Observational
100
Changsha, Shanghai
2022-11-01
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)
DrugsSHR-4602·IBI354·JSKN003·TQB2868
Fudan University
Phase 2
716
Shanghai
2022-11-01
Recruiting
Pre-operative Therapy in Breast Cancer
NCT05621564Breast Cancer
RenJi Hospital
Observational
6,032
Shanghai
2022-11-01
Active, closed
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
Eye & ENT Hospital of Fudan University
Not applicable
111
Harbin, Jinan, Shanghai
2022-11-01
Recruiting
Yingbin Liu, MD, PhD, FACS
Observational
1,000
Shanghai
2022-10-30
By invitation
Shanghai Changzheng Hospital
Phase 2
20
Shanghai
2022-10-28
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Beijing, Shanghai
2022-10-25
Active, closed
Acute Health Effects of High Temperature Exposure
NCT05575752Cardiovascular System, Respiratory System, Cognitive Function
Fudan University
Not applicable
30
Shanghai
2022-10-23
Active, closed
Yin Ping
Not applicable
264
Shanghai
2022-10-20
Recruiting
Fudan University
Phase 2
93
Shanghai
2022-10-18
Active, closed
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
52
Shanghai
2022-10-13
Recruiting
Shanghai Chest Hospital
Phase 1/2
140
Shanghai
2022-10-13
Recruiting
Combined Immunosuppression for Pediatric Crohn's Disease
NCT05043870Crohn Disease, Infliximab, Immunosuppression, Children, Only
DrugInfliximab
Children's Hospital of Fudan University
Phase 4
128
Shanghai
2022-10-10
Active, closed
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Recruiting
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
NCT07632365Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
Shanghai Chest Hospital
Phase 1/2
108
Shanghai
2022-10-09
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Beijing, Shanghai, Tianjin
2022-10-03
Recruiting
Children's Hospital of Fudan University
Observational
30
Shanghai
2022-10-01
Recruiting
Shanghai Tong Ren Hospital
Phase 4
160
Shanghai
2022-10-01
Recruiting
Fudan University
Not applicable
600
Shanghai
2022-10-01
Recruiting
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
NCT05575804Advanced/ Metastatic Her-2 Positive Breast Cancer
DrugPyrotinib
Fudan University
Phase 1/2
32
Shanghai
2022-10-01
Not yet open
Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese
NCT05435898Cardiovascular Diseases, Cardiovascular Morbidity, Subclinical Organ Damage, Digital Health
Shanghai 10th People's Hospital
Observational
4,000
Shanghai
2022-10-01
Recruiting
PK/PD of Caspofungin in Children Severe Infection
NCT04961593Pharmacokinetics, Infection, Fungal
DrugCaspofungin
Children's Hospital of Fudan University
Observational
60
Shanghai
2022-10-01
Recruiting
Ruijin Hospital
Not applicable
20
Shanghai
2022-10-01
Recruiting
Cell Free DNA in Mature B-cell Lymphoma
NCT04088422Mature B-Cell Lymphoma
Ruijin Hospital
Observational
320
Shanghai
2022-09-28
Active, closed
Hoffmann-La Roche
Phase 3
122
Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou
2022-09-27
Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
Fudan University
Phase 3
354
Shanghai
2022-09-27
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900Coronary Artery Disease, Acute Coronary Syndrome
CoreAalst BV
Phase 4
2,500
Shanghai, Shandong, Sichuan
2022-09-22
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
102
Shanghai
2022-09-21
Active, closed
Shen Feng
Observational
122
Shanghai
2022-09-20
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
324
Shanghai, Hangzhou
2022-09-15
Recruiting
RenJi Hospital
Not applicable
484
Shanghai
2022-09-14
Active, closed
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Recruiting
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
NCT04728724Non-small Cell Lung Cancer Stage III
DrugSintilimab
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2022-09-10
Active, closed
Fudan University
Phase 2
30
Shanghai
2022-09-10
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Active, closed
GlaxoSmithKline
Phase 3
110
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
38
Shanghai
2022-09-05
Recruiting
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
256
Shanghai
2022-09-01
Recruiting
RenJi Hospital
Not applicable
160
Shanghai
2022-09-01
Recruiting
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
NCT05495035Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
19
Hefei, Jinan, Tianjin, Shanghai
2022-09-01
Recruiting
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413Cancer Diagnosis, Liver Cancer, Adult, Cancer Screening, Colorectal Cancer (CRC)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Nanchang, Shanghai, Hangzhou
2022-09-01
Recruiting
Shanghai 6th People's Hospital
Observational
200
Shanghai
2022-09-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
56
Shanghai
2022-09-01
Recruiting
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
NCT05240950Colorectal Cancer, Metastatic Liver Cancer
Changhai Hospital
Phase 1
18
Shanghai
2022-08-25
Recruiting
Fudan University
Not applicable
80
Nanning, Zhengzhou, Changsha, Shanghai, Kunming, Hangzhou
2022-08-25
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-25
Recruiting
Shanghai Zhongshan Hospital
Observational
600
Shanghai
2022-08-22
Recruiting
L & L Bio Co., Ltd., Ningbo, China
Phase 1
100
Shanghai
2022-08-12
Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery
Children's Hospital of Philadelphia
Observational
900
Guangzhou, Shanghai, Shenyang, Sichuan
2022-08-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
NCT05447208Preimplantation Genetic Testing, Growth Hormone, Age, Parental
DrugGrowth Hormone
ShangHai Ji Ai Genetics & IVF Institute
Phase 3
400
Shanghai
2022-08-01
Recruiting
Children's Hospital of Fudan University
Not applicable
120
Shanghai
2022-08-01
Recruiting
Huashan Hospital
Observational
3,000
Shanghai
2022-08-01
Active, closed
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
NCT05306028Pancretic Cancer, Diabete Mellitus
DrugMetformin
Fudan University
Phase 2
20
Shanghai
2022-08-01
Active, closed
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
DrugXelox
Fudan University
Phase 2
94
Shanghai
2022-08-01
Recruiting
Fudan University
Phase 1/2
52
Shanghai
2022-08-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Observational
200
Shanghai
2022-07-27
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Recruiting
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Active, closed
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
NCT05316935Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
DrugsGnRHa·Letrozole
Xiaojun Chen
Phase 2/3
80
Shanghai
2022-07-13
Active, closed
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
NCT06390904Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
NCT06379113Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
DrugLetrozole
Xiaojun Chen
Phase 2/3
29
Shanghai
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsOlaparib·Bevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
Hrain Biotechnology Co., Ltd.
Phase 2
100
Shanghai, Wenzhou
2022-07-12
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Beijing, Nanjing, Shanghai
2022-07-08
Active, closed
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Active, closed
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT06196827Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 1
9
Beijing, Shanghai
2022-07-02
Recruiting
Fudan University
Phase 2
198
Shanghai
2022-07-02
Active, closed
ZhanYJ
Not applicable
150
Shanghai
2022-07-01
Not yet open
Shanghai Zhongshan Hospital
Not applicable
323
Shanghai
2022-07-01
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Recruiting
Shanghai Proton and Heavy Ion Center
Not applicable
48
Shanghai
2022-07-01
Not yet open
Observation of the Natural Course of Age-related Macular Degeneration
NCT05418231Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai
2022-07
Recruiting
Fudan University
Phase 2
90
Shanghai
2022-06-30
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Active, closed
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Active, closed
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
Active, closed
Genmab
Phase 2
264
Beijing, Shanghai
2022-06-14
Recruiting
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
NCT05316493Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity
DrugMegestrol Acetate
Xiaojun Chen
Phase 2/3
172
Shanghai
2022-06-13
Active, closed
Fudan University
Not applicable
56
Shanghai
2022-06-09
Recruiting
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
Active, closed
Effect of FMD on Colorectal Cancer Patients
NCT05384444Fasting Mimicking Diet, Colorectal Cancer
Fudan University
Not applicable
602
Shanghai
2022-06-08
Recruiting
Astellas Pharma Inc
Phase 1
681
Beijing, Xuhui District, Shanghai
2022-06-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
By invitation
Preservation of Venous Valvular Function After PMT for Acute DVT
NCT05588284Acute Deep Venous Thrombosis of Femoral Vein (Disorder)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Not applicable
100
Chuzhou, Shanghai, Taizhou
2022-06-06
Active, closed
Shanghai Zhongshan Hospital
Not applicable
1,016
Shanghai
2022-06-05
Active, closed
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003Clinical High Risk, Psychosis, Remission, Conversion
Brigham and Women's Hospital
Observational
2,617
Shanghai
2022-06-02
Active, closed
A Multi-center Retrospective Study of INO Treating B-ALL
NCT07238907Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin, Venetoclax
DrugInotuzumab Ozogamicin
Ruijin Hospital
Observational
102
Shanghai
2022-06-01
By invitation
Shanghai 10th People's Hospital
Not applicable
300
Shanghai
2022-06-01
Recruiting
Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment
NCT05326399Liver Transplantation, Renal Insufficiency, Chronic
RenJi Hospital
Observational
369
Shanghai
2022-06-01
Not yet open
Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes
NCT05294653Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus, Juvenile Diabetes
Shanghai Jiao Tong University School of Medicine
Observational
300
Shanghai
2022-06-01
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2
61
Shanghai
2022-06-01
Recruiting
Huashan Hospital
Phase 3
1,050
Guiyang, Kaili, Liupanshui, Zunyi, Shanghai
2022-05-23
Recruiting
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
214
Shanghai
2022-05-18
Active, closed
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
526
Shanghai
2022-05-13
Active, closed
Eli Lilly and Company
Phase 1
260
Beijing, Nanchang, Shanghai
2022-05-11
Recruiting
Incyte Corporation
Phase 2
98
Beijing, Shanghai
2022-05-05
Recruiting
Actelion
Phase 3
280
Beijing, Changsha, Nanjing, Qingdao, Shanghai, Xi'an
2022-05-04
Active, closed
Sanofi
Phase 3
104
Beijing, Chengdu, Guangzhou, Shanghai
2022-05-03
Not yet open
Fudan University
Phase 2
42
Shanghai
2022-05-01
Recruiting
Shanghai 10th People's Hospital
Observational
5,000
Shanghai
2022-05-01
Recruiting
Children's Hospital of Fudan University
Observational
5,000
Shanghai
2022-04-30
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
By invitation
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Active, closed
Sanofi
Phase 3
43
Taipei, Beijing, Guangzhou, Shanghai
2022-04-18
Active, closed
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
Recruiting
Huashan Hospital
Not applicable
2,000
Shanghai
2022-04-01
Recruiting
Ruijin Hospital
Observational
250,000
Shanghai
2022-03-29
Active, closed
GlaxoSmithKline
Phase 1
152
Chengdu, Jinan, Shanghai, Wuhan
2022-03-22
Recruiting
Huashan Hospital
Observational
2,000
Shanghai
2022-03-21
Active, closed
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
Recruiting
Ruijin Hospital
Phase 3
340
Shanghai
2022-03-15
Active, closed
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Active, closed
Sanofi
Phase 3
122
Beijing, Shanghai, Taiyuan, Zhengzhou
2022-03-11
Active, closed
Fudan University
Phase 2
104
Shanghai
2022-03-11
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
Prizvalve® Transcatheter Atrioventricular Valve Replacement Study
NCT05275088Atrioventricular Annular Calcification, Failed Prosthetic Atrioventricular Valve/ Annulus Repair
Shanghai NewMed Medical Co., Ltd.
Not applicable
15
Shanghai
2022-03-09
Active, closed
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Recruiting
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
NCT04973306Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
DrugTislelizumab
Shanghai Zhongshan Hospital
Phase 2/3
176
Shanghai
2022-03-02
Recruiting
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Recruiting
Shanghai Zhongshan Hospital
Observational
384
Shanghai
2022-03-01
Recruiting
Shanghai At Risk for Alzheimer's Disease: a Cohort Study
NCT05597410Alzheimer Disease, Dementia, Neurodegenerative Diseases, Cognitive Impairment
Ruijin Hospital
Observational
3,418
Shanghai
2022-03-01
Active, closed
Janssen Research & Development, LLC
Phase 2
151
Beijing, Chengdu, Hangzhou, Shanghai
2022-03-01
Recruiting
Fudan University
Phase 2
83
Shanghai, Ürümqi
2022-02-26
Recruiting
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Recruiting
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Not applicable
94
Shanghai
2022-02-15
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
30
Guangzhou, Shanghai
2022-02-11
Recruiting
Takeda
Phase 3
120
Beijing, Zhengzhou, Shanghai, Hangzhou
2022-02-10
Recruiting
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
NCT04527419Carcinoma, Non-Small-Cell Lung
Fudan University
Not applicable
545
Shanghai
2022-02-09
Recruiting
ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
NCT03786003Carcinoma, Non-Small-Cell Lung
Fudan University
Not applicable
1,086
Shanghai
2022-02-09
Active, closed
Hrain Biotechnology Co., Ltd.
Early Phase 1
18
Shanghai
2022-02-09
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Recruiting
RenJi Hospital
Observational
84
Shanghai
2022-02-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
96
Shanghai
2022-02-01
Active, closed
Effectiveness of Treatments for Cirrhosis With Varicose Veins
NCT06961474Esophageal Varices Bleeding, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,900
Shanghai
2022-02-01
Recruiting
Shanghai 6th People's Hospital
Observational
60
Shanghai
2022-02-01
Active, closed
Amgen
Phase 1/2
329
Chongqing, Fuzhou, Shanghai
2022-02-01
Recruiting
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
NCT05260671Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
DrugsPenpulimab·Cetuximab
Eye & ENT Hospital of Fudan University
Phase 2
48
Changchun, Shanghai
2022-01-25
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an
2022-01-24
Recruiting
Shanghai Hansoh Biomedical Co., Ltd
Phase 1
177
Shanghai
2022-01-05
Active, closed
Xiangyun Zong
Not applicable
258
Shanghai, Hangzhou
2022-01-03
Recruiting
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Observational
160
Zhangzhou, Shanghai
2022-01-01
Recruiting
Shanghai Chest Hospital
Not applicable
100,000
Shanghai
2022-01-01
Not yet open
Prospective Acute Myocardial Infarction Data Bank
NCT05121818Acute Myocardial Infarction
Shanghai Zhongshan Hospital
Observational
3,000
Shanghai
2022-01-01
Recruiting
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
NCT06391190Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
RenJi Hospital
Phase 1/2
20
Shanghai
2022-01-01
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Not applicable
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
By invitation
Effect of Hysteroscopic Metroplasty on Reproductive Outcome in Patients with RIF
NCT06847386Recurrent Implantation Failure, T-Shaped Uterus
Shanghai First Maternity and Infant Hospital
Not applicable
200
Shanghai
2022-01-01
Recruiting
Fudan University
Phase 3
459
Shanghai
2022-01-01
Not yet open
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
510
Shanghai
2022-01-01
Recruiting
Fudan University
Phase 3
366
Shanghai
2022-01-01
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
275
Shanghai
2021-12-31
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Hangzhou, Beijing, Shanghai, Tianjin
2021-12-27
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
ITM Solucin GmbH
Phase 3
259
Shanghai, Wuxi
2021-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
GlaxoSmithKline
Phase 2
366
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Shanghai
2021-12-14
Active, closed
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
56
Shanghai
2021-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
By invitation
TRIM25 in Septic Patients
NCT07320638Sepsis
Ruijin Hospital
Observational
65
Shanghai
2021-12-10
Active, closed
Taiho Pharmaceutical Co., Ltd.
Phase 1
78
Beijing, Shanghai
2021-12-01
Recruiting
Shanghai Mental Health Center
Observational
1,200
Shanghai
2021-12-01
By invitation
Observation on Obesity Undergoing XOWI
NCT05122936Obesity, Traditional Chinese Medicine
Feng Tao
Observational
500
Shanghai
2021-11-30
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
Womed
Not applicable
160
Guangzhou, Hangzhou, Shanghai
2021-11-29
Recruiting
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
NCT05142475Breast Cancer, Treatment Side Effects, Advanced Breast Cancer, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
50
Shanghai
2021-11-19
Recruiting
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Recruiting
The Impact of Atrial Pressure Change Before and After Combined Procedure
NCT05106270Atrial Fibrillation, Heart Failure
Shanghai 10th People's Hospital
Observational
100
Shanghai
2021-11-10
By invitation
Strategies for Proactive Health in People With Kidney Function Decline
NCT07245186Renal Insufficiency,Chronic, Dietary Intake Patterns, Malnutrition, Frailty
Huashan Hospital
Observational
1,800
Shanghai
2021-11-03
Recruiting
Top Down Versus Step up in Pediatric Ulcerative Colitis
NCT04999228Ulcerative Colitis, Infliximab, Children
Drugs5-ASA·Infliximab
Children's Hospital of Fudan University
Phase 4
40
Shanghai
2021-11-01
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-10-29
Active, closed
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
Shanghai Chest Hospital
Phase 2
35
Shanghai
2021-10-27
Active, closed
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
46
Shanghai
2021-10-26
Active, closed
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
NCT05174637Advanced/ Metastatic Solid Tumors
DrugFDA018-ADC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
78
Shanghai
2021-10-22
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
DrugsFludarabine·Cyclophosphamide
Changhai Hospital
Phase 1/2
30
Shanghai
2021-10-21
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 2
70
Shanghai
2021-10-18
Recruiting
Shanghai JMT-Bio Inc.
Phase 1
186
Shanghai
2021-10-12
Recruiting
High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
NCT05072626Biliary Atresia, Infant, Nutrition Support, Medium-chain Triglyceride
Children's Hospital of Fudan University
Observational
300
Shanghai
2021-10-11
Active, closed
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Recruiting
Fudan University
Phase 3
590
Shanghai
2021-10-08
Recruiting
Renal Artery Fibromuscular Dysplasia Registry
NCT05363748Renal Artery Fibromuscular Dysplasia
Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai
2021-10-01
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05125055Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
DrugsAlbumin paclitaxel·Adrucil·Toripalimab·Docetaxel
Shanghai Jiao Tong University School of Medicine
Phase 2/3
80
Shanghai
2021-10-01
Active, closed
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
NCT05098171Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Early Phase 1
50
Shanghai
2021-09-26
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Recruiting
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT05098197Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocyte
Shanghai Juncell Therapeutics
Early Phase 1
50
Shanghai
2021-09-26
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Recruiting
A Study of GC101 TIL in Advanced Melanoma (10hospital)
NCT05098184Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocyte
Shanghai Juncell Therapeutics
Early Phase 1
50
Shanghai
2021-09-26
Active, closed
Health Benefits of Air Purifiers in Primary School Students
NCT05016271Cardiopulmonary Function, Child
Fudan University
Not applicable
110
Shanghai
2021-09-22
Recruiting
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
NCT05059379Breast Cancer, Radiotherapy; Complications, Effect of Radiation Therapy
Fudan University
Phase 3
1,650
Shanghai
2021-09-20
Recruiting
Ruijin Hospital
Phase 3
640
Shanghai
2021-09-17
Active, closed
Hoffmann-La Roche
Phase 1/2
42
Beijing, Shanghai
2021-09-14
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
150
Shanghai
2021-09-10
Active, closed
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Recruiting
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
NCT05069857Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
DrugsApatinib·Camrelizumab
Shanghai Jiao Tong University School of Medicine
Phase 2
46
Shanghai
2021-09-01
Rows per page Showing 3001–3500 of 3879
Previous 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,879 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,418 of the 3,879 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 756 have not yet opened recruitment, 598 are active but closed to new participants, and 107 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.